196P - Pharmacogenetics of tamoxifen adjuvant therapy and its efficiacy: MDR1 polymorphisms in CYP2D6 extensive metabolizers with breast cancer

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Breast Cancer
Clinical research
Translational Research
Basic Scientific Principles
Basic Principles in the Management and Treatment (of cancer)
Presenter Sona Argalacsova
Authors S. Argalacsova1, O. Slanar2, H. Bakhouche2, M. Dražďáková3, O. Matoušková2, T. Zima3, L. Petruzelka4
  • 1Department Of Oncology, General Faculty Hospital-VFN Charles University, 12808 - Prague/CZ
  • 2Institute Of Pharmacology, First Faculty of Medicine, Charles University and General Teaching Hospital, Prague, Czech Republic,, 120 000 - Prague/CZ
  • 3Institute Of Clinical Biochemistry And Laboratory Diagnostics, First Faculty of Medicine, Charles University and General Teaching Hospital, Prague, 120 00 - Prague/CZ
  • 4Clinic Od Oncology, General Faculty Hospital-VFN Charles University, 12808 - Prague/CZ



The role of CYP2D6 polymorphisms in adjuvant breast cancer therapy has not been standardised until now. Recent pre-clinical evidence suggests that the active metabolite of tamoxifen, endoxifen, is a substrate for efflux pump P-glycoprotein (P-gp). The polymorphic MDR1 gene encoding the P-gp may thus represent a prognostic factor for the treatment outcome in addition to the previously studied pharmacogenetic factors. The aim of our study was to evaluate, if the polymorphisms within MDR1 gene and CYP2D6 gene alter tamoxifen adjuvant treatment efficacy in breast cancer.


Totally 252 women signed informed consent and participated in the study. After exclusion of poor metabolizers for CYP2D6, 227 women with estrogen receptor positive breast cancer were followed retrospectively for median period of 79 months. The primary analysis was conducted on time-to-event.


The cumulative observed recurrence rate was approximately 26.5%. The Cox-proportional hazard regression model revealed C3435T polymorphism, age and clinical tumor size at the time of diagnosis as significant covariates affecting the event free survival. The patients carrying at least one variant allele 3435T in MDR1 gene had significantly longer time to event survival resulting in hazard ratio of 0.44 (95%CI 0.21-0.92) as compared with CC3435 patients. For the G2677T/A polymorphism, a non-significant trend suggesting that the wt homozygous may had worse treatment outcome as compared with the heterozygous or homozygous subjects for the variant alleles was noted. The respective median event free survival times were 93, 103, and 126 months.


Wild type homozygous genotype in MDR1 polymorphism C3435T predicts for worse treatment outcome of tamoxifen adjuvant therapy. This should be taken into account as a potential pharmacogenetic biomarker for the drug efficacy.


All authors have declared no conflicts of interest.